Hypophosphatemic osteomalacia associated with tenofovir: A multidisciplinary approach is required

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 4, Issue 1, 2012, Pages

  De Socio, Giuseppe Vittorio L ^a   Fabbriciani, Gianluigi ^b   Massarotti, Marco ^b   Messina, Salvatore ^a   Cecchini, Enisia ^a   Marasini, Bianca ^c  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHANE; ALKALINE PHOSPHATASE; ATAZANAVIR; CALCITRIOL; CLONAZEPAM; COLECALCIFEROL; EMTRICITABINE; ETIDRONIC ACID TC 99M; LEVOMEPROMAZINE; MEDRONATE TECHNETIUM TC 99M; PHOSPHATE; RALTEGRAVIR; RISPERIDONE; RITONAVIR; TENOFOVIR; VALPROIC ACID; ZIDOVUDINE;

ADULT; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE PAIN; BORDERLINE STATE; CASE REPORT; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; GAIT DISORDER; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; KIDNEY TUBULE DISORDER; LUMBAR SPINE; MALE; MUSCLE WEAKNESS; OSTEOPENIA; PHOSPHATURIA; SPINE FRACTURE;

EID: 84875976383     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2012.025     Document Type: Article

References (23)

1. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49: 298-308. http://dx.doi.org/10.1097/QAI.0b013e3181893e8e PMid:18845956
2. Mazzotta E, Agostinone A, Rosso R, Di Biagio A, De Socio GV, Cappelletti A, Zicolella R, Polilli E, Bonfanti P, Di Matteo L, Manzoli L, Parruti G. Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study. J Bone Miner Metab. 2011;29:383-388. http://dx.doi.org/10.1007/s00774-010-0245-5 PMid:21258827
3. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.HIV Med. 2005; 6:341-6. http://dx.doi.org/10.1111/j.1468-1293.2005.00318.x PMid:16156882
4. Di Biagio A, Rosso R, Monteforte P, Russo R, Rovetta G, Viscoli C. Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. J Med Case Reports. 2009; 3:8136. http://dx.doi.org/10.4076/1752-1947-3-8136 PMid:19830218 PMCid:2737799
5. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C Jr, Klein D. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010; 53:62-9. http://dx.doi.org/10.1097/QAI.0b013e3181be6be2 PMid:19838127
6. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect. 2005;51: E61-5. http://dx.doi.org/10.1016/j.jinf.2004.08.031 PMid:16038754
7. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, Connolly JO. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482-7 http://dx.doi.org/10.1111/j.1468-1293.2009.00716.x PMid:19459988
8. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354-908.
9. De Socio GV, Ricci E, Parruti G, Maggi P, Madeddu G, Quirino T, Bonfanti P. Chronological and biological age in HIV infection. J Infect. 2010;61:428-30. http://dx.doi.org/10.1016/j.jinf.2010.09.001 PMid:20833202
10. De Socio GV. Schizophrenia, drug therapy, and monitoring. N Engl J Med. 2004;350:415-6. http://dx.doi.org/10.1056/NEJM200401223500420
11. De Socio GVL, Fanelli L, Longo A, Stagni G. Adherence to antiretroviral therapy in HIV patients with psychiatric comorbidity. J Acquir Immune Defic Syndr 2004; 36:1109-1110. PMid 15247568
12. Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, Penco G, Rosella E, Miccolis S, Melzi S, Mura MS, Landonio S, Ricci E, Quirino T; CISAI Group. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother. 2008;62:6-11. http://dx.doi.org/10.1016/j.biopha.2007.04.008
13. Jhaveri MA, Mawad HW, Thornton AC, Mullen NW, Greenberg RN. Tenofovir-associated severe bone pain: I cannot walk! J Int Assoc Physicians AIDS Care (Chic). 2010;9:328-34. http://dx.doi.org/10.1177/1545109710376595 PMid:20923957
14. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, Martinez E, Reiss P, Visnegarwala F, Carr AD; INSIGHT SMART Body Composition Substudy Group. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519-29. http://dx.doi.org/10.1097/QAD.0b013e32832c1792 PMid:19531929 PMCid:2748675
15. Fabbriciani G, De Socio GV, Massarotti M. Antiretroviral therapy and adverse skeletal effects. Mayo Clin Proc. 2011;86:916-7. http://dx.doi.org/10.4065/mcp.2011.0341 PMid:21878605 PMCid:3257996
16. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010 1;51:496-505. http://dx.doi.org/10.1086/655681 PMid:20673002
17. Créput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS. 2003 11;17:935-7
18. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S; California Collaborative Treatment Group 578 Team. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102-8 http://dx.doi.org/10.1086/524061 PMid:18171292
19. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283-90. http://dx.doi.org/10.1086/499048 PMid:16355343
20. Madeddu G, Quirino T, Carradori S, Ricci E, Grosso C, Penco G, De Socio G, Rossella E, Palvarini L, Marconi P, Melzi S, Mura MS, Bonfanti P; Gruppo CISAI. Renal toxicity in HIV-infected patients receiving HAART including tenofovir. Infez Med. 2006;14:125-34. PMid:17127826
21. Hirotaka Komaba, Takatoshi Kakuta, Masafumi Fukagawa, Diseases of the parathyroid gland in chronic kidney disease, Clin Exp Nephrol 2011;15:797-809. http://dx.doi.org/10.1007/s10157-011-0502-5 PMid:21818548
22. De Socio GV, Fabbriciani G, Fanelli L, Leli C, Callarelli L, Scarponi AM. Low bone mineral density in institutionalized patients with HIV and psychiatric co-morbidity. Infez Med. 2008;16:86-90. PMid:18622148
23. European AIDS Clinical Society. Web site.http://www.europeanaidsclinicalsociety.org/guidelines/g2.htm Accessed November, 2011.